Pipeline

We’re working to identify more unmet medical needs and focus our research where it is needed most. Our growing pipeline includes therapies aimed at providing new solutions in cancer care and rare diseases where no options currently exist, with a goal to help lift the burden of cancer for patients.

Robust R&D Pipeline with significant potential

Near-term and long-term pipeline, securing launches over the coming years.

Notes

The safety and efficacy of the product candidates in the above table have not been established. There is no guarantee that they will receive health authority approval or become commercially available in any country for the uses being investigated.

1. Infigratinib is co-developed globally by Helsinn Healthcare S.A. and QED Therapeutics, Inc., a BridgeBio company, in all fields of use except for skeletal dysplasias and except in the following territories: China, Hong Kong and Macau
2. Approved in U.S., Canada and Australia – Regulatory process ongoing in other territories
3. Mycosis fungoides-type cutaneous T-cell lymphoma
4. Chemotherapy-Induced Nausea and Vomiting  –  In Japan Arokaris®  only includes Fosnetupitant
5. Approved in Japan
6. Non-Small Cell Lung Cancer